Firm seeks effective treatment for Sickle Cell Disease

Oklahoma-based EpimedX may be nearing a treatment for Sicle Cell Disease.

 
BY REX SMITHERMAN | Published: November 27, 2012    Comment on this article Leave a comment

Advertisement


DID YOU KNOW?

If both parents have the sickle cell gene, there is a one in four chance of having a baby with Sickle Cell Disease. Eighty-five percent of the approximately 100,000 SCD sufferers in the U.S. are black, 10.6 percent are American Indian, and 4.4 percent are Hispanic-American, Asian-American, or Caucasian.

“It took us 15 years to think of the idea of how this might work,” Broyles said. “Then another 10 years to show out how it works in principal, and then another 10 years to advance the technology.”

Broyles and EpimedX co-founder Robert Floyd are building the firm's first investment round. The funds will be used to complete preclinical tests and file the drug with the FDA. The next funding round will be for clinical trials.

Thanks to the perseverance of the EpimedX scientists and entrepreneurs, this Oklahoma firm is on a path to bring relief to Sickle Cell Disease sufferers around the world.

Rex Smitherman is interim president and CEO of i2E Inc., a nonprofit corporation that mentors many of the state's technology-based startup companies. i2E receives state appropriations from the Oklahoma Center for the Advancement of Science and Technology. Contact Smitherman at i2E_Comments@i2E.org.

Page 2 of 2




If you prefer your thoughts to appear in The Oklahoman's Opinion section, we encourage you to submit a letter to the editor.


Today's Hot Stock Picks
Market Research, Due Diligence, Expert Analysis--Get Free Alerts!
www.OTCStockPick.com
Don't Buy High Speed
Before Comparing Broadband Providers. Best High Speed Internet Deals.
ISP1.us/High-Speed

Business Photo Galleriesview all